Myeloma cell lines are heterogeneous in their response to cytokines and inhibitors of intracellular signaling

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cell lines serve as a model for studying the molecular organization of cancer cells in humans. Several myeloma cell lines were screened for proliferation response to cytokines (IL-6, -10, -15, -21, IGF-1, HGF, TNF-a) and inhibitors of intracellular signaling (JAK2\STAT3-, PI-3K-, МАРК- pathways and NFkB). Striking heterogeneity of the response was revealed suggesting different proliferation control patterns. With advent of targeted anti-cancer therapy, much effort could be needed to find specific targets in individual MM patients.

About the authors

V. V. Baykov

St. Petersburg State Medical University

Author for correspondence.
Email: shabanov@mail.rcom.ru

кафедра патологической анатомии

Russian Federation, St. Petersburg

М. Borset

Institute of cancer research and molecular medicine, Norwegian university of science and technology

Email: shabanov@mail.rcom.ru
Russian Federation, Trondheim

U.-M. Fagerli

Institute of cancer research and molecular medicine, Norwegian university of science and technology

Email: shabanov@mail.rcom.ru
Russian Federation, Trondheim

A. Sundan

Institute of cancer research and molecular medicine, Norwegian university of science and technology

Email: shabanov@mail.rcom.ru
Norway, Trondheim

References

  1. Bergsagel Р. L., Kuehl W. М. Chromosome translocations in multiple myeloma // Oncogene. 2001. Vol. 20. P. 5611-5622.
  2. Bergsagel D. E., Sprague С. C., Austin C., Griffith К. M. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NC-8806) // Cancer Chemotherapy Rep. 1962. Vol. 21. P. 87.
  3. Alexanian R., Haul A., Khan A. U. et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens//JAMA. 1969. Vol. 208. P. 1680-1685.
  4. Fermand J. Р., Ravaud Р, Chevret S. et al. Highdose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial // Blood. 1998. Vol. 92. P. 3131-3136.
  5. Anderson К. C. Targeted therapy for multiple myeloma // Semin. Hematol. 2001. Vol. 38. P. 286-294.
  6. Kavano M., Hirano T.. Matsuda T et al. Autocrine generation and essential requirement of BSF/IL-6 for human multiple myeloma // Nature. 1988. Vol. 332. P. 83-85.
  7. Klein B., ZhangX G., Jourdan M. et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 // Blood. 1989. Vol. 73. P. 517-526.
  8. van Zaanen H. С. T., Lokhorst H. M.. van Aardcn L. A. et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: phase 1 dose-escalating study // Brit. J. Haematol. 1998. Vol. 102. P. 783-790.
  9. Georgii-Hemming P, Wiklund H. J., LjunggrenO., Nilsson K. Insulin-like growth factor 1 is growth and survival factor in human multiple myeloma cells // Blood. 1996. Vol. 88. P. 2250-2258.
  10. Borset M., Lien E., Expevik T. et al. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines // J. Biol. Chern. 1996. Vol. 271. P. 24655-24661.
  11. H. Lu Z. Y., Zhang X. G., Wijdenes J. et al. Interleukin 10 is a growth factor for human myeloma cells // Blood. 1995. Vol. 85. P. 2521-2527.
  12. Hjorth-Hansen H., Waage A., Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells // Brit. J. Haematol. 1999. Vol. 106. P. 28-34.
  13. Brenne A.-T, Baade Ro T., Waage A. et al. Interleukin 21 is a growth and survival factor for human myeloma cells // Blood. 2002. Vol. 99. P. 3756-62.
  14. Borset M., Waage A., Brekke O. L., Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line // Eur. J. Haematol. 1994. Vol. 53. P. 31-37.
  15. Ponzetto C., Bardelli A., Zhen Z. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor scatter factor-receptor family // Cell. 1994. Vol. 77. P. 261-271.
  16. Vivanco J., Sawyers C. L. The phosphatidilinosi- tol 3-kinase - Akt pathway in human cancer // Nature reviews: cancer. 2002. Vol. 2. P. 489-501.
  17. Shi Y., Hsu J.-H., Hu L. et al. Signal pathways involved in activation of p70S6K and phosphorilation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6 II J. Biol. Chern. 2002. Vol. 277. P. 15712-15720.
  18. Chen E, Castranova V., Shi X. New insights into the role of Nuclear Factor-кВ in cell growth regulation // Am. J. Pathol. 2001. Vol. 159. P. 387-397.
  19. Platanias L. Map kinase signaling pathways and hematologic malignancies // Blood. 2003. Vol. 101. P. 4667-1679.
  20. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gpl30: a model of the cytokine system // Cytokine Growth Factor Rev. 1997. Vol. 8. P. 241-252.
  21. Hjertner O., Hjorth-Hansen H., Borset M. et al. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells//Blood. 2001. Vol. 97. P. 516-522.
  22. Pellat Deceunynck C., Amiot M., Bataille R. etal. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after (letter) // Blood. 1995. Vol. 86. P. 4001-4002.
  23. Drexler H. G., Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia /7 Leukemia Res. 2000. Vol. 24. P. 681-703.
  24. Hideshima T, Nakamura N., Chauhan D., Ander¬son К. C. Biologic sequelae of interkeukin-6 induced PI-3K/AKT signaling in multiple myeloma // Oncogene. 2001. Vol. 20. P. 5991-6000.
  25. Qiang Y. W., Kopantzev E., RudikoffS. Insulinlike growth factor-1 signaling in multiple myeloma: downstream elements, functional correlates and pathway crosstalk H Blood. 2002. Vol. 99. P. 4138-4146.
  26. Quintanilla-Martinez L., Kremer M., Specht K. et al. Analysis of signal tansducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and Cyclin DI dys-regulation are mutually exclusive events // Am. J. Pathol. 2003. Vol. 162. P. 1449-1461.
  27. Borset M., Hjort-Hansen H., Johnsen A.-C. et al. Apoptosis and NFkB activation induced by agonistic Fas antibodies in the human mveloma cell line OH-2: amplification of Fasmediated apoptosis by tumor necrosis factor II Eur. J. Haematol. 1999. Vol. 63. P. 345-353.
  28. Rohde J., Heitman J., Cardenas M. The TOR kinases link nutrient sensing to cell growth // J. Biol. Chern. 2001. Vol. 276. P. 9583-9586.
  29. Schwab G., Siegall С. B., Aarden L. A. et al. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266 II Blood. 1991. Vol. 77. P. 587-593.
  30. Ни L., Shi Y., Gera J. et al. Downstream effectors of oncogenic ras in multiple myeloma cells // Blood. 2003. Vol. 101. P. 3126-3135.
  31. Ogata A.. Chauhan D., Urashima M. et al. IL-6 triggers multiple myeloma cell growth via the Rasdependent mitogen activated protein kinase cascade // J. Immunol. 1997. Vol. 159. P. 2212-2220.
  32. Xu Е-H., Sharma S., Gardner A. et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of JNK/SAPK pathway // Blood. 1998. Vol. 92. P. 241-251.
  33. Zhang B., Fenton R. G. Proliferation of IL-6 independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2) // J. Cell Physiol. 2002. Vol. 193. P. 42-54.
  34. Burger R., Guenther A., Bakker F. et al. Gpl30 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma// Hematol. J. 2001. Vol. 2. P. 42-53.
  35. Hideshima T., Chauhan D., Richardson P. et al. NFkB as a therapeutic target in multiple myeloma // J. Biol. Chern. 2002. Vol. 277. P. 16639-16647.
  36. Sheehy A. M., Schlissel M. S. Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line // J. Biol. Chern. 1999. Vol. 274. P. 8708-8716.
  37. Hov H, Holt R. U., Ro T. B. et al. A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells // Clin. Cancer Res. 2004. Vol. 10. P. 6686-6694.
  38. Репе F, Claessans Y.-E., Muller O. et al. Role of the phosphatidilinositol 3-kinase/Akt and mTOR /P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma II Oncogene. 2002. Vol. 21. P. 6587-6597.
  39. Hsu J.-H., Shi Y, Krajewski S. et al. The АКТ kinase is activated in multiple myeloma tumor cells // Blood. 2001. Vol. 98. P. 53-55.
  40. Ishikawa H., Tsuyama N., Abroun S. et al. Interleukin-6, CD45 and the Src-kinases in mueloma cell proliferation // Leukemia lymphoma. 2003. Vol. 44. P. 1477-1481.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2006 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.